To Assess The 8-Year Clinical Outcomes Of Implantation Of An Implantable Collamer Lens (Icl) With A Central Port (Ks-Aquaport; Evo-Icl) For Moderate To High Myopia And Myopic Astigmatism

TO ASSESS THE 8 YEARS CLINICAL OUTCOMES OF IMPLANTATION OF AN IMPLANTABLE COLLAMER LENS  (ICL) WITH A CENTRAL PORT (KS - AQUAPORT : EVO ICL ) FOR MODERATE TO HIGH MYOPIA AND MYOPIC ASTIGMATISM

RETROSPECTIVE STUDY. PRIVATE SET UP 

This retrospective study comprised a total of 177 eyes of 106 patients with spherical equivalents of −7.99 ± 3.33 D [mean ± standard deviation], who underwent EVO-ICL implantation. We evaluated the safety, efficacy, predictability, stability, and adverse events of the surgery, at 1 month, and 1, 2, 4, 6, and 8 years postoperatively.

The logarithm of the minimal angle of resolution (LogMAR) uncorrected distance visual acuity (UDVA) and corrected distance visual acuity (CDVA) were −0.07 ± 0.17 and −0.30 ± 0.09, respectively, at 8 years postoperatively. The safety and efficacy indices were 1.18 ± 0.24 and 0.89 ± 0.28, respectively. At 8 years, 83 and 93% eyes were within ± 0.5 D and ± 1.0 D of the targeted correction, respectively. Change in manifest refraction from 1 month to 8 years postoperatively was −0.13 ± 0.30 D. We found that neither significant intraocular pressure (IOP) rise (including pupillary block) nor significant endothelial cell loss occurred in any case throughout the 8-year observation period

Current ICL implantation with central port technology offered good continuous outcomes for all measures of safety, efficacy, predictability, and stability for correcting moderate to high myopic errors over a long period, thereby suggesting its long-term viability as a surgical approach for the treatment of such eyes.